Vaccine Therapy in Preventing Cytomegalovirus in Healthy Participants

DISEASE CHARACTERISTICS: * Cytomegalovirus (CMV) seropositivity or seronegativity * HLA A\*0201 positive OR positive tetramer-binding using CMV peptide 495-503 with HLA A2 subtypes other than HLA A\*0201 * A2-CMV-Tet cells ≤ 10\^8/L PATIENT CHARACTERISTICS: * Platelet count within 1.5 times upper level of normal (ULN) * The following blood and chemistry studies must be normal: * Sodium * Potassium * Chloride * Carbon dioxide * Glucose * BUN * Creatinine * Uric acid * WBC * Hemoglobin * Hematocrit * The following studies must be ≤ ULN: * Albumin * Alkaline phosphatase * AST and ALT * Lactic dehydrogenase * Total bilirubin * Hepatitis B virus surface antigen negative * Hepatitis C virus seronegative * No diagnosis that is associated with immunodeficiency (e.g., HIV) * No active infection that requires treatment * No known cardiac disease including hypertension and/or high cholesterol * No serious abnormalities by EKG (in participants ≥ 50 years of age) * Not pregnant * Negative pregnancy test * Fertile participants must use effective contraception during study and for 6 weeks after the fourth and last dose of vaccine * No history of allergic reaction to tetanus toxoid * No history of any of the following: * Cancer other than basal cell carcinoma of the skin * Depression * Allergic diathesis, as defined by a history of asthma * Anaphylaxis * Generalized urticaria or daily use of antihistamines * Episodic (more than once in the pa…